Reviva Pharmaceuticals Holdings reported a narrowed net loss of approximately $2.3 million for the third quarter of 2026, compared to $4.0 million in the same period last year. The company holds $17.5 million in cash as of September 30, 2026, but noted that the planned start of its RECOVER-2 Phase 3 trial in the first half of 2027 remains contingent on securing additional financing.
Neutral
🤖 50%
The Q3 2026 net loss narrowed to about $2.3 million ($0.17/share) from about $4.0 million a year earlier, and cash rose to about $17.5 million, both mildly positive. But the RECOVER-2 Phase 3 enrollment planned for 1H 2027 is explicitly subject to additional financing, offsetting the positives, and the FDA feedback expected in Q4 2026 is still pending.
Catalysts
- • FDA feedback on the new brilaroxazine formulation expected in Q4 2026
- • U.S. patent office granted Track 1 priority examination for the new-formulation composition of matter patent, with potential patent protection through 2046
Risk Factors
- • RECOVER-2 patient enrollment targeted for 1H 2027 is subject to receipt of additional financing
- • Stock trades on OTCQB with limited liquidity and volatility; planned Nasdaq relisting application only in 1H 2027 and may be delayed or unsuccessful